The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Some Rheumatic Diseases Tied to Higher Risk of Severe COVID-19

Some Rheumatic Diseases Tied to Higher Risk of Severe COVID-19

June 23, 2020 • By Megan Brooks

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Patients with some inflammatory rheumatic conditions are at higher risk for hospital-diagnosed COVID-19 infection compared with the general population, but it depends on the condition and therapy used to treat it, according to a study from Spain.

You Might Also Like
  • People with Rheumatic Diseases Should Pay Extra Attention to Self-Care During COVID-19
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
  • Psoriasis Tied to Higher Risk of Serious Liver Disease

It’s now clear that older patients and those with some common diseases are at increased risk for more severe COVID-19 disease, “but we did not know about patients with rheumatic diseases,” coauthor Dr. Jose Pablos of the Research Institute Hospital 12 de Octubre, Madrid, tells Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For their study, Dr. Pablos and colleagues used data from more than 26,000 patients being followed in hospital rheumatology departments for positive SARS-CoV-2 PCR tests and a reference population of 2.9 million adults.

Overall, patients with any rheumatic disease had 1.32-fold greater odds of hospital-diagnosed COVID-19 than the reference population (0.76% vs. 0.58%), the researchers report in Annals of the Rheumatic Diseases. However, not all diseases conferred the same risk.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients with rheumatoid arthritis or psoriatic arthritis showed similar COVID-19 rates compared with the reference population despite their older age.

However, specific groups of inflammatory arthritis, including patients with spondyloarthritis (0.89%; odds ratio, 1.54) and those on targeted-synthetic and biologic disease-modifying antirheumatic drug therapy (0.94%; OR, 1.60) had higher rates of COVID-19. “This suggests that these specific immunomodulators may increase the risk for COVID-19, similarly as for other viral infections,” the authors report.

Conventional DMARDs did not seem to increase the risk of COVID-19.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

COVID-19 prevalence was relatively low in patients with systemic lupus erythematosus (0.62%; OR, 1.07), despite an expected greater use of corticosteroids and immunosuppressants. A possible explanation is the frequent use of antimalarials, which may provide some protection, the researchers suggest.

The relatively low prevalence in SLE contrasts with the significant increase observed in all other autoimmune or immune-mediated inflammatory diseases (AI/IMID overall prevalence, 1.11%; OR, 1.92; AI/IMID non-SLE, 1.54%; OR, 2.69). Patients with polymyalgia rheumatica giant cell arteritis (PMR-CGA) also had an increased rate of COVID-19 (1.45%; OR, 2.53).

COVID-19 was associated with older age in some, but not all diagnostic groups.

Dr. Pablos says this information could help “tailor specific recommendations on COVID-19 to rheumatic patients. The mentioned groups [autoimmune, biologic therapy] are at higher risk to get more severe COVID-19 than the general population” and should adhere to general prevention measures and seek early medical care if they develop symptoms.

“Other groups of patients [lupus, arthritis on conventional therapy] should also know that they are not at increased risk. We also always recommend maintaining previous therapies to avoid worsening of the rheumatic disease that may also increase the risks for infections and many other complications,” says Dr. Pablos.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: coronavirus, COVID-19, Rheumatic Disease

You Might Also Like:
  • People with Rheumatic Diseases Should Pay Extra Attention to Self-Care During COVID-19
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
  • Psoriasis Tied to Higher Risk of Serious Liver Disease
  • Some Jobs Tied to Higher Risk of RA

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)